Cytori Therapeutics opens European sales and marketing center in Switzerland and unveils Cytori Exchange

ZUG, Switzerland--(BUSINESS WIRE)--With the foundation of Cytori GmbH, Cytori Therapeutics, Inc. (NASDAQ:CYTX) has opened its new sales and marketing center in Europe. The new Swiss site means that most of the company’s activities in Europe and the Middle East will now be carried out by sales and customer-service staff in Zug.

“Cytori GmbH plays a major role in expanding our business activities and key initiatives in Europe.”

Cytori’s President Marc Hedrick explains: “Cytori GmbH plays a major role in expanding our business activities and key initiatives in Europe.” A conscious decision was taken to select a central location in Switzerland for Cytori GmbH, enabling us to fully exploit growth opportunities within the region and beyond from the new site.

One of our main initiatives for 2011 involves introducing the Cytori Exchange further-training program, which encompasses a range of Operations Live seminars and workshops. Here, the focus is on regenerative medicine and plastic surgery. The aim of the first series of seminars is to familiarize specialist medical staff with the latest applications and developments in regenerative medicine and plastic surgery as practiced in hospitals and doctors’ surgeries.

Eric Daniels, Managing Director of Cytori GmbH, states: “Clinical interventions which combine the principles of regenerative medicine and plastic surgery produce excellent results for patients and doctors alike. The Cytori Exchange Program is designed to help specialist medical staff to constantly stay abreast of the rapid progress being made in the field of regenerative medicine and plastic surgery. We’re very pleased to offer this new, eagerly awaited program.”

You can find further information on Cytori Exchange at www.cytoriexchange.com.

Today, Cytori announced positive, recapitulatory results from the RESTORE-2 study, which examined the application of a minimally invasive intervention to rectify defects following a lumpectomy. A copy of the press release is available on request.

Cytori GmbH’s new address in Zug is:

Rigistrasse 3
CH-6300 Zug
Switzerland
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]

***

About Cytori
Cytori is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. The Celution^® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets, while we seek regulatory clearance in the United States. Our StemSource^® product line is sold globally for cell banking and research applications. www.cytori.com

Information relating to future events
This press release contains information relating to future events, trends and business prospects, such as the effects of Cytori GmbH on our business activities and initiatives in Europe, which could influence our future operating results and financial position. Such information is subject to risks and uncertainties; therefore, our actual result and our real financial position may deviate considerably from the forecasts provided. Risks and uncertainties include past operating losses, the need for further financing, ambiguities relating to intellectual property rights and official guidelines pursuant to the compilation of clinical data and results therefrom, the reliance on the performance of third parties as well as other risks and uncertainties which Cytori has listed under “risk factors” in the entries for the U.S. Securities and Exchange Commission, such as those featured in our Annual Report on Form 10-K for the business year ending December 31, 2009. Further, Cytori shall not assume any responsibility for updating or revising information relating to future events in this press release in order to take into account any events, trends or circumstances that may arise after the publication date.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.